Cancer Center, Samsung Medical Center, and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea.
Cancer Res Treat. 2005 Aug;37(4):251-6. doi: 10.4143/crt.2005.37.4.251. Epub 2005 Aug 31.
RhoA is a critical transducer of extracellular signals, which leads to organization of actin cytoskeleton, motility, adhesion and gene regulation. The present study aimed to explore whether RhoA influences the susceptibility of gastric cancer cells to chemotherapeutic drugs.
SNU638 cells were transfected with a mock vector (pcDNA3.1), RhoA (pcDNA/RhoA), or constitutively active RhoA (pcDNA/caRhoA). MTT assay and Western blot analysis were performed to study the growth response to several chemotherapeutic drugs in the gastric cancer cell line, SNU638, with different RhoA levels.
RhoA significantly enhanced the resistance to lovastatin, 5-FU, taxol and vincristine, but did not affect the sensitivity to cisplatin or etoposide in SNU638. In the Western blot analysis, RhoA decreased the PARP cleavage, which was accompanied by a concurrent reduction in cell death. The gene expression profile after a cDNA microarray analysis demonstrated that RhoA was associated with the differential expression of 19 genes, including those involved in anti-oxidant defense, glucose metabolism, anti-apoptosis and protein turnover.
Gastric cancer cells with a high expression of RhoA could be resistant to chemotherapeutic drugs, such as taxol or vincristine, implying that treatment strategies aimed at inactivation of RhoA might be promising for improving the efficacy of these chemotherapeutic drugs.
RhoA 是细胞外信号的关键转导因子,可导致肌动蛋白细胞骨架的组织、运动、黏附和基因调控。本研究旨在探讨 RhoA 是否影响胃癌细胞对化疗药物的敏感性。
用 mock 载体(pcDNA3.1)、RhoA(pcDNA/RhoA)或组成型活性 RhoA(pcDNA/caRhoA)转染 SNU638 细胞。用 MTT 分析和 Western blot 分析研究 RhoA 水平不同的胃癌细胞系 SNU638 对几种化疗药物的生长反应。
RhoA 显著增强了 lovastatin、5-FU、紫杉醇和长春新碱的耐药性,但不影响 SNU638 对顺铂或依托泊苷的敏感性。Western blot 分析显示,RhoA 减少了 PARP 切割,同时细胞死亡减少。cDNA 微阵列分析后的基因表达谱表明,RhoA 与包括抗氧化防御、葡萄糖代谢、抗凋亡和蛋白质周转在内的 19 个基因的差异表达相关。
高表达 RhoA 的胃癌细胞可能对紫杉醇或长春新碱等化疗药物具有耐药性,这意味着针对 RhoA 失活的治疗策略可能有助于提高这些化疗药物的疗效。